Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressiva

Journal of Bone and Mineral Research

Volumn 25, Issue 6, 2010, Pages 1460-1462

  Gatti, Davide ^a   Viapiana, Ombretta ^a   Rossini, Maurizio ^a   Silvano, Adami ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Fibrodysplasia Ossificans Progressiva (FOP); PPAR ; Rosiglitazone; Thiazolidinediones

Indexed keywords

CHOLESTEROL; ETIDRONIC ACID; GLUCOSE; HEMOGLOBIN A1C; PREDNISONE; ROSIGLITAZONE;

ADULT; ARTICLE; BODY HEIGHT; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KNEE FUNCTION; LOW DRUG DOSE; OSSIFYING MYOSITIS;

FEMALE; HUMANS; MIDDLE AGED; MYOSITIS OSSIFICANS; THIAZOLIDINEDIONES;

EID: 77953495378     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.091113     Document Type: Article

References (8)

1. Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22:191-205.
2. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 2006;38:525-527.
3. Smith R, Russell RGG, Wood CG. Myositis ossificans progressive: clinical features of eight patients and their response to treatment. J Bone Joint Surg Br. 1976;58B:48-57.
4. Deeks ED, Keam SJ. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2007;67:2747-2779. (Pubitemid 350224383)
5. Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with type 2 diabetes. Expert Opin Drug Saf. 2008;7:69-68.
6. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41-49. (Pubitemid 34742565)
7. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146:1226-1235.
8. Akune T, Ohba S, Kamekura S, et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113:846-855. (Pubitemid 38544143)